Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This trial will be conducted to evaluate the efficacy, safety and tolerability of SUNITINIB
as add-on therapy with a widely used second-line palliative FOLFIRI chemotherapy in patients
with chemo-refractory advanced or metastatic adenocarcinoma of stomach or lower esophagus
(mGC).
There is a clear scientific rationale for the use of Sunitinib to treat patients with mGC.
Despite recent therapeutic advances, the median overall survival (OS) in patients with mG is
still ≤ 12 months. Therefore, newer agents with novel mechanisms of action are desperately
needed for treatment of these patients.